Dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) — an anion channel found on epithelial cells of various tissues — causes cystic fibrosis and plays an important role in ...

- ALYFTREK™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR modulator therapies - - In head-to-head ...

Therapeutics Market Size accelerated to USD 10.60 billion in 2024, up from USD 9.22 billion in 2023, and is now projected to expand aggressively to USD 35.09 billion by 2033, recording a CAGR of 14.2% ...

DENVER - A recent retrospective study published in CHEST(Opens in a new window) evaluated the effects of cystic fibrosis transmembrane conductance regulator (CFTR) modulator use on pregnancy outcomes ...

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference - Oral presentation on outcomes following treatment ...

- Data presented on outcomes following treatment with CFTR modulators add to growing body of evidence that reduced level of sweat chloride is associated with improved clinical outcomes, particularly ...

BETHESDA, Md.--(BUSINESS WIRE)--The Cystic Fibrosis Foundation today announced its investment of $5 million in Sionna Therapeutics, a company founded in 2019. The company is focused exclusively on ...

- Deutivacaftor/tezacaftor/vanzacaftor approved for people with cystic fibrosis 6 years and older with at least one responsive mutation in the CFTR gene, including ...

According to DataM Intelligence, the Cystic Fibrosis (CF) Therapeutics Market Size accelerated to USD 10.60 billion in 2024, up from USD ...